hims glp-1 & Hers weight loss adds compounded injections The Unraveling of Hims' GLP-1

Further research is warranted to explore long-term outcomes and optimize treatment protocols for this patient population

Public Citizen contends that Novo Nordisk and Eli Lilly's obesity drugs are straining budgets so much that generics should be authorized.

The Risks: Unknown ingredients and contamination Incorrect dosages and life-threatening side effects No regulatory oversight or safety data Why This Is Critical: Patients are bypassing pharmacies and getting injections from sketchy online vendors This undermines real GLP1 therapies and can lead to serious harm As healthcare professionals, we must: Ask patients about the source of their medications Report adverse reactions to MedWatch Educate our patients about safe access and real prescriptions Lets advocate for ethical prescribing and responsible patient care in the GLP1 era

The incretin pathway is a self-regulating feedback system connecting the gut with the brain, pancreas, and liver

without HF: HR 0.44

Here are the details.